The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLI.a

Pulmonary edema, noncardiogenic (NCPE)

Publications

Davidoff S, Shah RD, Arunabh T

Gemcitabine-induced respiratory failure associated with elevated erythrocyte sedimentation rate (ESR).

Respiratory medicine 2006 Apr;100;760-3 — 2006 Apr — 760-3

Desramé J, Duvic C, Bredin C, Béchade D, Artru P, Brézault C, Defuentes G, Poirier JM, Dourthe LM, Coutant G, Chaussade S, de Gramont A, Algayres JP

[Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].

La Revue de medecine interne 2005 Mar;26;179-88 — 2005 Mar — 179-88

Sauer-Heilborn A, Kath R, Schneider CP, Höffken K

Severe non-haematological toxicity after treatment with gemcitabine.

Journal of cancer research and clinical oncology 1999 Nov;125;637-40 — 1999 Nov — 637-40

Tempero MA, Brand R

Fatal pulmonary toxicity resulting from treatment with gemcitabine.

Cancer 1998 May 01;82;1800-1 — 1998 May 01 — 1800-1